Announcements Trials
Browse Landscape

Phase

Phase NA 2

Status

Unknown 1Terminated 1

Sponsor Class

OTHER 2NETWORK 2INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other neoplasm 2Other hematologic neoplasm 2Myeloid 2Lymphoid 2Plasma cell 1

Conditions

Breast Neoplasms 8Neoplasms 4Multiple Myeloma 3Radiation Injuries 2Multiple Chronic Conditions 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Leukemia, Lymphocytic, Chronic, B-Cell 2Esophageal Neoplasms 2Cognitive Dysfunction 2Brain Neoplasms 2Substance-Related Disorders 1Sarcoma 1Rectal Neoplasms 1Prostatic Neoplasms 1Pathologic Complete Response 1Pain 1Osteosarcoma 1Neoplasms, Second Primary 1Neoplasms, Plasma Cell 1Nasopharyngeal Neoplasms 1Nasopharyngeal Carcinoma 1Mobility Limitation 1Melanoma 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma 1Leukemia 1Kidney Neoplasms 1Hyperthermia 1Hematologic Neoplasms 1Head and Neck Neoplasms 1

Interventions

Cyclophosphamide 82Imatinib Mesylate 81fludarabine phosphate 67fludarabine 62Whole-Body Irradiation 55Mycophenolic Acid 54Tacrolimus 42nilotinib 40Busulfan 39Dasatinib 32Cyclosporine 30Peripheral Blood Stem Cell Transplantation 28thymoglobulin 25Melphalan 25Thiotepa 24Cytarabine 24Granulocyte Colony-Stimulating Factor 23Antilymphocyte Serum 23Methotrexate 21Filgrastim 21Stem Cell Transplantation 20ponatinib 16Sirolimus 16sargramostim 14Cord Blood Stem Cell Transplantation 13Rituximab 11Cyclosporins 11Clofarabine 11venetoclax 10peginterferon alfa-2b 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Leukemia, Myelogenous, Chronic, BCR-ABL Positive × Patient Reported Outcome Measures × Clear all
NCT04663100 2023-12-04

Oral Adherence in Hematological Oncology Agents and Impact on Comorbid Therapy Adherence

University of Tennessee

Phase NA Unknown
30 enrolled
LymphoidMyeloidOther hematologic neoplasmOther neoplasmPlasma cell

Multiple Chronic Conditions, Leukemia, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Hematologic Neoplasms

NCT04595851 2022-11-22

Pharmacists Coordinated Care Oncology Model (PCOM) for Patients Taking Oral Anti-cancer Medications

University of Michigan Rogel Cancer Center

Phase NA Terminated
6 enrolled
LymphoidMyeloidOther hematologic neoplasmOther neoplasm

Multiple Chronic Conditions, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡